

**Sientra, Inc.**  
**Thanks for the Mammaries**

Derek C. Cheung  
Honne Capital  
December 14, 2015

# Table of Contents

---

- Background and Business
- Silimed Manufacturing Issues
- Sientra Reacts
- Market Opportunity
- NOL Carryforwards
- Conclusion

# Background and Business

# Background and Business

---

- Sientra, Inc. is headquartered in Santa Barbara, California
- Sientra was founded in 2006 by aesthetics industry veterans with venture capital financing
- In April 2007 Sientra gained rights to silicone breast implant clinical trials through the acquisition of Silimed-U.S. <sup>(1)</sup>

# Background and Business

---

- Sientra received FDA approval for its silicone breast implant products in March 2012
- Since then, Sientra has hired a full sales team, developed a business with revenues tracking \$50 million and has begun working toward profitability
- Breast implants account for virtually all of Sientra's sales

# Background and Business

- Sientra's breast implants are made of high-strength cohesive silicone gel


## Round



The round implant with the strongest cohesive gel on the market, yet soft to the touch.

- The only round implant made with HSC Silicone Gel for the desired look and feel
- Offers a fuller, more dramatic appearance in the upper portion of the breast
- Available in both a smooth surface and a textured surface

## Teardrop Shaped



The first FDA-approved shaped breast implant. Not too hard, not too soft.

- Our proprietary HSC+ Silicone Gel allows the implant to hold its shape without feeling too firm
- Designed to mimic the natural look and feel of a breast
- TRUE Texture<sup>®</sup> Surface designed to maintain the position of the implant in your body

# Background and Business

---

- Sientra product technology video:



# Background and Business

Market Valuation		Valuation Multiples		
Stock Price	\$4.30		\$	<i>Multiple</i>
Diluted Shares Out.	<u>18.0M</u>	Revenue 2014	44.7	—
Market Cap	\$77.4M	Revenue 2015E <sup>(1)</sup>	53.3	—
Net Cash	<u>(\$123.0M)</u>	EBIT 2014	(5.8)	—
Enterprise Value	(\$45.6M)	EBIT 2015E	—	—
		EPS 2014	(2.28)	—
		EPS 2015E	—	—


1. Sientra FY 2015 revenue guidance reaffirmed on August 12, 2015

# Background and Business

<i>Fiscal Year Ending 12/31</i>			
<i>\$ (000s omitted)</i>	2012	2013	2014
Net Sales	10,447	35,171	44,733
<i>Growth YoY</i>	∞	236.7%	27.2%
COGS	2,352	8,592	11,500
Gross Profit	8,095	26,579	33,233
<i>Gross Margin %</i>	77.5%	75.6%	74.3%
SG&A	31,527	44,786	39,018
Operating Loss	(23,432)	(18,207)	(5,785)
<i>Operating Margin %</i>	(124.3%)	(51.8%)	(12.9%)
Other (Expense) Income	(1)	(918)	(26)
Pre-Tax Loss	(23,433)	(19,125)	(5,811)
Income Taxes	0	0	0
Net Loss	(23,433)	(19,125)	(5,811)

Source: Sientra 2014 Form 10-K

# Background and Business



Source: Reuters; Sientra SEC filings

# Silimed Manufacturing Issues

# Silimed Manufacturing Issues

---

- All of Sientra's products are supplied by Silimed Indústria de Implantes in Brazil
- Silimed is the third largest manufacturer of breast implants worldwide
- Silimed has been manufacturing breast implants since 1981 with product approvals in 75 countries

# Particle-gate

---

- In September 2015 TÜV SÜD—a German inspection company—established that “the surfaces of some Silimed devices were contaminated with particles.” (1)
- The Australian sponsor of Silimed implants identified the particles as silica and cotton (2)
- TÜV SÜD claimed that Silimed was not able to adequately explain the source of the impurities nor could it provide sufficient measures to remedy the situation

1. Sientra Q3 2015 Form 10-Q

2. Therapeutic Goods Administration update on September 25

# Particle-gate

---

- TÜV SÜD suspended Silimed's CE certification through December 17
- (A CE certification indicates to government officials that a product may be legally marketed in Europe)
- This suspension did not apply to Sientra's breast implants, as they are sold only in the U.S. under FDA regulations

# Particle-gate

---

- On September 23, 2015, the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) issued a statement about Silimed's CE certification
- The MHRA did not require a recall of Silimed products, only a halt to distribution in the UK
- Notably, the MHRA stated that “there has been no indication at this time that these issues would pose a threat to patient safety.”

# Particle-gate

---

- On October 2, 2015, the Brazilian regulatory agency ANVISA (due to TÜV SÜD's actions) temporarily suspended the manufacturing and shipment of all medical devices made by Silimed, including products manufactured for Sientra
- ANVISA reiterated that no risks to patient health have been identified in connection with implanting Silimed products

# Doctors' Opinions

---

- “It has been known that particulate matter exists on implants, and these particles are sterilized along with the implant sterilization process. The presence of these sterile particles has not been shown to cause any adverse effects.”
- “The presence of sterile cotton and silica on the surface of silicone implants is common to all three companies’ [(Allergan, Mentor, Sientra)] manufacturing processes.”
- “Implants are routinely washed in betadine or antibiotic solution prior to implantation. Therefore, the particulates are cleansed from the surface of the implant and never make it into the patient’s body.”

# Doctors' Opinions

---

- “Understand that the silicone particles are most likely from production of the implant shell, so there is nothing different about the material in comparison to the implant itself. Cotton lint is something that will occur with any surgery, due to use of the sterile cotton towels, gauze, and surgical sponges.”
- “There is no evidence of harm that would be caused by either of these, so the European decision is just precautionary until this issue is resolved.”

# Wall Street Analysts

---

- “While Sientra’s products are manufactured at the same facility where Silimed manufactures the products in question, they follow separate protocols and thus we think it’s premature to extrapolate that the FDA will necessarily take similar action.”
- “Versus the products Silimed makes for the European market, the products Silimed manufactures for Sientra are manufactured in separate runs using different processes (guided by FDA compliance protocols). Therefore it may not be correct to make comparisons between MHRA’s observations and speculated FDA observations.”

# Wall Street Analysts

---

- “We’d note that Silimed’s last inspection from the FDA—which looked at processes associated with Sientra products and compliance with good manufacturing practices—was in mid-2013. Additionally, the facility has undergone multiple FDA inspections over the last 10 years, and these inspections have never resulted in a Form-483 observation.”

# Silimed Manufacturing Issues - Fire

---

- On October 22, 2015 a fire broke out at one of Silimed's two manufacturing buildings
- The fire occurred in the building where Sientra's breast implants are primarily manufactured (building F2)

# Silimed Manufacturing Issues - Fire

---

- Silimed has indicated that a smaller production facility in building F1, which was not impacted by the fire, has the potential to be modified for breast implant manufacturing
- “At the same time, we will build a new factory to replace the one that burned.”
- “Our inventories, which were not affected by the fire, will be made available as soon as they are released by the regulatory agencies.”

# Sientra Reacts

# Sientra Reacts - Voluntary Hold

---

- On October 9, 2015 Sientra **voluntarily** placed a hold on the sale of all devices manufactured by Silimed and recommended that plastic surgeons discontinue implanting the devices until further notice
- The FDA reiterated that no reports of adverse events and no risks to patient health have been identified in connection with implanting Silimed-manufactured products

# Sientra Reacts - Management Change

---

- On November 12, 2015 Hani Zeini stepped down as CEO and was immediately replaced by Jeffrey Nugent, a Sientra board member since July 2014 <sup>(1)</sup>
- Mr. Nugent conducted successful turnarounds as CEO of three companies: Neutrogena (acquired by Johnson & Johnson), Revlon and Precision Dermatology (acquired by Valeant Pharmaceuticals) <sup>(2)</sup>
- “Our immediate priority is to resolve the outstanding regulatory questions, maximize our existing inventory and ensure a stable manufacturing process moving forward.” <sup>(1)</sup>

1. Sientra press release dated November 12, 2015  
2. Meet Sientra - Biography

# Sientra Reacts

---

- Sientra is conducting a review of its implants with the help of third-party experts in quality management systems and good manufacturing processes
- In addition, the company is testing its existing finished goods inventory and will continue to be in communication with the FDA prior to resuming shipments
- Current inventory supply is approximately 12 months
- “We expect to be in a position to present our findings to the FDA by the end of calendar year 2015.”

# Sientra Reacts

---

- As of September 30, 2015 Sientra had \$148 million of unrestricted cash and only \$25 million of debt
- Sientra subsequently paid off all loans and is conserving its net cash of over \$100 million
- Sientra has a program in place to retain salespeople and other talented employees

# Market Opportunity

# Market Opportunity

---

- The U.S. market for breast implants and tissue expanders exceeded \$600 million in 2013 <sup>(1)</sup>
- Between 1997 and 2013, the number of breast augmentation and breast reconstruction procedures grew at a CAGR of 7.3% and 4.4%, respectively <sup>(1)</sup>
- Based on FY 2015 sales guidance Sientra was on track to capture 9% of the market <sup>(2)</sup>, despite its unique policy of selling products only to board-certified plastic surgeons

1. Sientra 2014 Form 10-K  
2. Sientra Q3 2015 Form 10-Q

# Market Opportunity

---

- Sientra has only two competitors: Allergan and Mentor (a subsidiary of Johnson & Johnson)
- Pfizer's acquisition of Allergan may result in distraction at the breast implant division
  - "I expect that Pfizer will try to sell the breast implant business."
- Mentor does not appear to be committed to the breast implant business
  - "Mentor is reducing R&D spending on breast implants, focusing on cash generation rather than on growth."

# Market Opportunity

---

- Sientra does not have any patents or patent applications and spends less than \$5 million annually on R&D <sup>(1)</sup>
- The company is primarily a marketing operation, consisting of 46 salespeople as of Q2 2015 <sup>(1)</sup>

# Reaching Profitability

---

- Prior to the Silimed manufacturing issues, we estimate that Sientra was on track to reach profitability by Q1 2016
- In March 2015 Sientra provided FY 2015 revenue guidance of between \$52.5 million and \$54 million, with the midpoint representing a YoY increase of 19% <sup>(1)</sup>
- Sientra reaffirmed FY 2015 revenue and gross margin guidance (73%) in August <sup>(2)</sup>

1. Sientra 8-K filed March 11, 2015  
2. Sientra 8-K filed August 12, 2015

# Operating Leverage

---

- Sientra achieved YoY sales growth in Q2 2015 of 21.2%, which was primarily driven by the increasing size and effectiveness of its sales force and greater familiarity with its products by surgeons
- Marketing dollars appeared to achieve a more efficient outcome after engaging on RealSelf—the world’s largest online community for learning and sharing information about cosmetic procedures

# NOL Carryforwards

# NOL Carryforwards

---

- As of December 31, 2014 Sientra had federal net operating loss carryforwards of approximately \$101.2 million, which expire in various years beginning in 2027
- Sientra assigns zero value to NOLs on its balance sheet, because existing NOLs may be subject to limitations arising from previous and future “ownership changes”
- Sientra has not completed a section 382 analysis to determine if an ownership change has occurred

# Section 382 Analysis

---

- A section 382 “ownership change” occurs if immediately after an owner shift, there is a greater than 50% change in the value of the stock owned by five percent shareholders over a rolling three-year period <sup>(1)</sup>
- Abingworth’s \$65 million Series C funding round in 2012 <sup>(2)</sup> and Sientra’s subsequent IPO may have constituted an ownership change
- If so, Sientra’s NOLs will be limited to approximately \$3.5 million

1. Internal Revenue Code  
2. Sientra Crunchbase profile

# NOL Carryforwards

---

- However, there is some probability that Sientra did not undergo an “ownership change”
- Assuming a corporate tax rate of 35%, Sientra’s NOLs would translate into approximately \$35 million of deferred tax assets, or 40% of the current market capitalization
- We expect Sientra to conduct a section 382 analysis upon reaching profitability

# Conclusion

# Conclusion

---

- We expect Sientra shares to rerate higher in Q1 2016 once the company reverses the voluntary hold on U.S. sales
- The shares should rerate further once Silimed regains manufacturing ability lost from the fire at building F2
- With over \$100 million in cash, zero debt and a year's supply of finished goods inventory Sientra has time to wait for these developments to occur

# Conclusion

---

- Sientra trades at a negative enterprise value, despite substantial industry recognition, intellectual property and future earning power
- Sientra has honest and able management in Mr. Jeffrey Nugent, who has led numerous companies through difficult times
- Once Sientra passes the current state of uncertainty, investors will apply a growth premium to the stock
- We expect Sientra shares to double in less than a year

# Disclaimer

---

Funds advised by Honne Capital have purchased shares of Sientra, Inc. This analysis is based on publicly available information, interviews with Sientra's management, the Food & Drug Administration and numerous other industry sources. Honne presents this analysis "as is" and believes the information contained to be reliable. All information provided in this presentation is for informational purposes only and should not be deemed as investment advice or a recommendation to purchase or sell any specific security. Honne reserves the right to change its investment position at any time without further notice to any party.

These materials shall not constitute an offer to buy any interests in Honne Capital or any of its affiliates. Such an offer to buy interests may only be made pursuant to a definitive subscription agreement between Honne and an investor.

This presentation is confidential and may not be reproduced without prior written permission from Honne.